Neurizon Therapeutics (ASX:NUZ) has moved to bolster its leadership as it prepares to advance its lead drug candidate NUZ 001 through late-stage clinical trials and build readiness for future commercialisation.
Effective immediately, Dr Ross Murdoch joins the board as an independent non-executive director, bringing more than 30 years of global pharmaceutical and biotechnology experience, as well as direct involvement in neurology and neurodegenerative disease programs.
Murdoch’s background spans senior roles at AstraZeneca, GlaxoSmithKline, and Shire Pharmaceuticals, and extensive time working in the United States, where he gained experience in that country’s clinical development environments, capital markets engagement, and scaling companies internationally.
He is currently chief executive officer and president of Extractas Bioscience and has prior ASX leadership and governance experience, including time as CEO of Avecho Biotechnology.
The appointment coincides with the immediate retirement of Dr Michael Thurn, who steps down from the board following his earlier transition from the role of managing director and chief executive officer. Interim executive chairman Sergio Duchini said the board sought to strengthen capability across commercial strategy, operational execution, and US market engagement to support both near-term clinical milestones in the HEALEY ALS Platform Trial and longer-term value creation for shareholders.
Dr Murdoch said he looked forward to working with the board and management to advance NUZ 001 and help position Neurizon for its next phase of growth. He will stand for election by shareholders at the next annual general meeting in line with ASX listing rules and the company constitution.